Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18568866 | 0.88 | GAA (0.68) | GAAL3MBTL1FFAR1KDM4EALDH1A1 | |
| SCHEMBL8273178 | 0.86 | GAA (0.55) | GAAL3MBTL1FFAR1KDM4EALDH1A1 | |
| SCHEMBL22781472 | 0.83 | GAA (0.55) | GAAL3MBTL1FFAR1KDM4EALDH1A1 | |
| SCHEMBL18569320 | 0.79 | GAA (0.56) | GAAL3MBTL1FFAR1KDM4EALDH1A1 | |
| SCHEMBL17366169 | 0.78 | MDM2 (0.58) | GAAALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL18568890 | 0.76 | ADORA2A (0.38) | GAAL3MBTL1FFAR1KDM4EALDH1A1 | |
| SCHEMBL10997308 | 0.76 | CA1 (0.53) | — | |
| Ubisindine SCHEMBL191543 | 0.74 | TSHR (0.62) | GAAL3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL17366155 | 0.74 | CYP2C9 (0.56) | POLBMAPT | |
| SCHEMBL4464212 | 0.73 | KDM4E (0.61) | GAAL3MBTL1FFAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-2960233-A1 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | GAA 2043/4885L3MBTL1 1063/4885FFAR1 3767/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | GAA 2043/4885L3MBTL1 1063/4885FFAR1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.